📈Zacks Investment Research today
Roche Reports Positive Data from Tecentriq Combination Study.
Roche Holding AG RHHBY announced positive results from a phase III study, IMmotion 151 on immuno-oncology drug Tecentriq.
The study evaluated the efficacy and safety of Tecentriq and Avastin versus Sutent in renal cell carcinoma patients.
December 11, 2017 – Zacks.com
Roche – Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer
https://www.roche.com/media/store/releases/med-cor-2017-12-11.htm
Novartis Reports Updated Results from Kymriah’s JULIET Study – December 11, 2017.
Novartis AG NVS announced updated results from the pivotal JULIET study.
It showed sustained complete responses at six months with Kymriah suspension for intravenous infusion, in adult patients with a difficult-to-treat cancer- relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Zacks.com
https://www.zacks.com/stock/news/285583/novartis-reports-updated-results-from-kymriahs-juliet-study
General Dynamics Wins $46M Deal for Submarine Maintenance – December 11, 2017.
General Dynamics Corp.’s GD Electric Boat division recently secured a $45.9-million contract for the New England Maintenance Manpower Initiative.
Per the terms of the deal, the company will carry out non-nuclear maintenance of submarines based at Naval Submarine Support Facility in New London, CT.
The deal has been awarded by The Naval Sea Systems Command, Washington, D.C.
Zacks.com